NCT06279494View on ClinicalTrials.gov

Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

March 31, 2025

Conditions
Acute LeukemiaMyelodysplastic SyndromesSevere Aplastic Anemia
Interventions
DRUG

Sirolimus

Orally (concentration 5-10ng/ml) from -1 to +100d post haplo-HSCT

DRUG

Abatacept

5mg/kg subcutaneous, -1/+5/+14/+28/+42/+56d post haplo-HSCT

DRUG

MMF

0.5g bid orally, from -3d to +60d post haplo-HSCT

DRUG

ATG

2.5 mg/kg, from -5d to -2d

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT06279494 - Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors | Biotech Hunter | Biotech Hunter